GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NanoString Technologies Inc (OTCPK:NSTGQ) » Definitions » 5-Year RORE %

NanoString Technologies (NanoString Technologies) 5-Year RORE % : 7.09% (As of Sep. 2023)


View and export this data going back to 2013. Start your Free Trial

What is NanoString Technologies 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. NanoString Technologies's 5-Year RORE % for the quarter that ended in Sep. 2023 was 7.09%.

The industry rank for NanoString Technologies's 5-Year RORE % or its related term are showing as below:

NSTGQ's 5-Year RORE % is ranked better than
61.01% of 636 companies
in the Medical Devices & Instruments industry
Industry Median: 0.66 vs NSTGQ: 7.09

NanoString Technologies 5-Year RORE % Historical Data

The historical data trend for NanoString Technologies's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NanoString Technologies 5-Year RORE % Chart

NanoString Technologies Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.16 -10.38 4.49 6.08 5.10

NanoString Technologies Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.60 5.10 5.67 7.89 7.09

Competitive Comparison of NanoString Technologies's 5-Year RORE %

For the Medical Instruments & Supplies subindustry, NanoString Technologies's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NanoString Technologies's 5-Year RORE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NanoString Technologies's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where NanoString Technologies's 5-Year RORE % falls into.



NanoString Technologies 5-Year RORE % Calculation

NanoString Technologies's 5-Year RORE % for the quarter that ended in Sep. 2023 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -3.53--2.58 )/( -13.4-0 )
=-0.95/-13.4
=7.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2023 and 5-year before.


NanoString Technologies  (OTCPK:NSTGQ) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


NanoString Technologies 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of NanoString Technologies's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


NanoString Technologies (NanoString Technologies) Business Description

Traded in Other Exchanges
Address
530 Fairview Avenue North, Seattle, WA, USA, 98109
NanoString Technologies Inc is engaged in the development, manufacturing and commercialization of instruments, consumables, and services for efficiently profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. Its core technology includes proprietary chemistries that enable the labeling and counting of single molecules. The firm uses its technology to develop tools for scientific and clinical research, primarily in the fields of genomics and proteomics. It offers two product platforms such as nCounter Analysis System or nCounter, and GeoMx Digital Spatial Profiler or DSP system both include instruments, related consumables, and software. NanoString Technologies generates revenue from the sale of products and related services and collaborations.
Executives
Jonathan Todd Garland officer: Chief Commercial Officer C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
K Thomas Bailey officer: Chief Financial Officer 1618 STATION STREET, VANCOUVER A1 V6A 1B6
R Bradley Gray director, officer: President and CEO 530 FAIRVIEW AVENUE NORTH, SUITE 2000, SEATTLE WA 98109
William Young director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Waite Charles P Jr director, 10 percent owner 11023 NE 116TH STREET, KIRKLAND WA 98034
Gregory Norden director 16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005
Elisha W Finney director C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304
Teresa M. Foy director 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Joseph M Beechem officer: SVP, Research & Development 530 FAIRVIEW AVENUE NORTH, SUITE 2000, SEATTLE WA 98109
John D. Gerace officer: Chief Commercial Officer C/O NANOSTRING TECHNOLOGIES, INC., 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Kirk Malloy director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
J. Chad Brown officer: SVP, Sales & Marketing 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Robert Hershberg director 3005 FIRST AVENUE, SEATTLE WA 98121
Janet George director 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Dana E. Rollison director 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109